BioStem Technologies Inc. (OTC:BSEM) Stock In Focus After Receiving Institutional Review Board (IRB) Approval to Advance Clinical Trial

February 26, 2025February 26, 2025 Jon Williams

The medical technology sector continues to be a vibrant one, and investors are always on the lookout for companies in the sector to track. One of the companies that could be worth tracking is BioStem Technologies Inc. (OTC:BSEM), which was in focus on Monday after it made a key new announcement. Let’s take a closer look.

The Update

The company, involved in the development of placenta-based products for next-generation wound care, announced that one of its clinical studies had been granted approval by the IRB (institutional review board). The study would work on the evaluation of the proprietary BioETrain Amnion Chorion in the treatment of VLU (venomous leg ulcers). In the study, the efficacy of the product would be compared to the standard of care that is in place with other forms of non-healing VLUs in the market.

Continued Progress

In the news release, it was revealed that it was the third prospective clinical trial being performed by BioStem Technologies across the range of wound indications that it had developed. The company also continued to work on advancing its allograft products with the aim of displaying greater effectiveness for the benefit of healthcare professionals and patients.

CEO Quote

Jason Matuszewski, CEO of BioStem, stated, “This is our third prospective clinical trial across various wound indications, and we continue to advance these trials for our allograft products with the goal of demonstrating clinical superiority for healthcare professionals and payers. We previously announced the publication of a peer-reviewed study demonstrating breakthrough results with the application of this product for diabetic foot ulcers. BioStem is confident that the benefits of our technology will become evident in additional indications such as VLUs and looks forward to providing updates as the trial progresses.”

Fundamentals

P/E Ratio	20.39
PEG Ratio	0.07
Price to Book	9.29
Price to Cash Flow	14.0891
Price to Free Cash Flow	14.4779
Total Sales (TTM)	210.40 M
Revenue per Share (TTM)	9.96
Shares Outstanding	16.338 M
Share Float (%)	11.85 M (72.55%)

Jon Williams

Jon graduated from the University of Michigan with a degree in finance. He is an avid investor and enjoys reporting on the markets. When he is not in front of a computer he enjoys playing golf and watching basketball.